A blockchain is a public ledger, yet the proceeds of crypto fraud still disappear every day. Using the AdBlast pyramid scheme, which according to press reports harmed up to 90,000 people and caused losses of around USD 32 million, we trace how investor money is moved from a “private wallet” to cash withdrawn at an ATM. We then look at the criminal, fiscal and regulatory tools available in Poland as of November 2026, a moment when MiCA’s transitional period has expired but Poland still has no national crypto-asset supervisor, and at what this means for victims seeking to recover their funds.
After three years of negotiations, the reform of EU pharmaceutical legislation is one step away from completion. A new regulation and a new directive will replace the current Community code and the EMA Regulation, reshaping data and market protection periods, the rules for orphan medicines, the Bolar exemption and supply obligations. Originator and generic companies alike will need to revisit their strategies, and Poland faces a thorough overhaul of its Pharmaceutical Law.
What the Overdeck divorce teaches Polish advisers of wealthy international families
The divorce of Two Sigma co-founder John Overdeck, fought without a prenuptial agreement over a fortune estimated at around USD 8 billion, shows how quickly a private dispute can become a risk for a business, its partners and its investors. This study uses the case as a starting point to compare the New Jersey prenuptial agreement with the Polish marital property agreement (intercyza) and sets out what Polish law permits, what it prohibits and what should be negotiated when advising wealthy international families.
We are proud to announce that KG Legal Kiełtyka Gładkowski has been named a winner in the inaugural European Legal Awards 2026, hosted by EU Business News. The firm received the title Most Trusted Cross-Border Law Firm 2026 – Poland.
Poland’s Ministry of Health wants to place medicines with different active substances in a single reimbursement limit group where they work in a similar way, and to reward hospitals for choosing the cheapest therapy available. The change is meant to bring prices down and free up funds for innovative treatment, but clinicians warn that cost equivalence is not the same as clinical equivalence. We examine how the proposed baskets of equivalent therapeutic technologies could affect physicians’ autonomy, patients’ rights and competition in the pharmaceutical market, and what safeguards the legislation should contain. KG LEGAL KIELTYKA GLADKOWSKI supports international pharmaceutical, biotechnology and healthcare businesses operating in Poland. For legal assistance with pharmaceutical regulation, reimbursement and market access, contact our team at office@kg-legal.pl.
